1Associate Professor, Department of Pharmacology, Gian Sagar Medical College and Hospital, Village Ram Nagar, District Patiala-140601, Punjab, India
2Lecturer, Department of Pathology, Shri Sukhmani Dental College and Hospital, Dera Bassi, District Mohali-140603, Punjab, India
Email id: *drpsmatreja@yahoo.co.in
**drjaspreetkaur@rediffmail.com
Online published on 28 August, 2014.
Canagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers the renal threshold for glucose, resulting in a greatly increased urinary glucose excretion and reduced blood glucose concentrations in patients with hyperglycaemia. This group of drugs has been used as monotherapy and as an adjunct therapy to all antidiabetic drugs. The present review evaluates the concept, therapeutic potential and limitations of canagliflozin as potential antidiabetic agent.
Canagliflozin, Diabetes, Sodium-glucose co-transporter, Metformin, Renal glucose threshold
